Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Liquid Biopsy to Identify Actionable Genomic Alterations.

Ou SI, Nagasaka M, Zhu VW.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):978-997. doi: 10.1200/EDBK_199765.

PMID:
30231331
2.

Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion.

Farago AF, Taylor MS, Doebele RC, Zhu VW, Kummar S, Spira AI, Boyle TA, Haura EB, Arcila ME, Benayed R, Aisner DL, Horick NK, Lennerz JK, Le LP, Iafrate AJ, Ou SI, Shaw AT, Mino-Kenudson M, Drilon A.

JCO Precis Oncol. 2018;2. doi: 10.1200/PO.18.00037. Epub 2018 Jul 23.

PMID:
30215037
3.

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.

Drilon A, Ou SI, Cho BC, Kim DW, Lee J, Lin JJ, Zhu VW, Ahn MJ, Camidge DR, Nguyen J, Zhai D, Deng W, Huang Z, Rogers E, Liu J, Whitten J, Lim JK, Stopatschinskaja S, Hyman DM, Doebele RC, Cui JJ, Shaw AT.

Cancer Discov. 2018 Aug 9. doi: 10.1158/2159-8290.CD-18-0484. [Epub ahead of print]

PMID:
30093503
4.

Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.

Lin JJ, Zhu VW, Schoenfeld AJ, Yeap BY, Saxena A, Ferris LA, Dagogo-Jack I, Farago AF, Taber A, Traynor A, Menon S, Gainor JF, Lennerz JK, Plodkowski AJ, Digumarthy SR, Ou SI, Shaw AT, Riely GJ.

J Thorac Oncol. 2018 Jun 20. pii: S1556-0864(18)30714-7. doi: 10.1016/j.jtho.2018.06.005. [Epub ahead of print]

PMID:
29935304
5.

Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.

Schrock AB, Zhu VW, Hsieh WS, Madison R, Creelan B, Silberberg J, Costin D, Bharne A, Bonta I, Bosemani T, Nikolinakos P, Ross JS, Miller VA, Ali SM, Klempner SJ, Ou SI.

J Thorac Oncol. 2018 Sep;13(9):1312-1323. doi: 10.1016/j.jtho.2018.05.027. Epub 2018 Jun 5.

6.

The allure of 'ALUR'.

Nagasaka M, Zhu VW, Ou SI.

Ann Oncol. 2018 Jun 1;29(6):1344-1346. doi: 10.1093/annonc/mdy144. No abstract available.

PMID:
29688274
7.

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

Lin JJ, Zhu VW, Yoda S, Yeap BY, Schrock AB, Dagogo-Jack I, Jessop NA, Jiang GY, Le LP, Gowen K, Stephens PJ, Ross JS, Ali SM, Miller VA, Johnson ML, Lovly CM, Hata AN, Gainor JF, Iafrate AJ, Shaw AT, Ou SI.

J Clin Oncol. 2018 Apr 20;36(12):1199-1206. doi: 10.1200/JCO.2017.76.2294. Epub 2018 Jan 26.

PMID:
29373100
8.

METex14-Positive NSCLC: Time to Take the Therapy to the Target to Aim for a Cure?

Zhu VW, Ou SI.

J Thorac Oncol. 2017 Aug;12(8):1180-1182. doi: 10.1016/j.jtho.2017.06.009. No abstract available.

9.

Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib.

Zhu VW, Cui JJ, Fernandez-Rocha M, Schrock AB, Ali SM, Ou SI.

Lung Cancer. 2017 Aug;110:32-34. doi: 10.1016/j.lungcan.2017.05.018. Epub 2017 May 22.

10.

Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.

Ou SI, Cui J, Schrock AB, Goldberg ME, Zhu VW, Albacker L, Stephens PJ, Miller VA, Ali SM.

Lung Cancer. 2017 Jun;108:228-231. doi: 10.1016/j.lungcan.2017.04.003. Epub 2017 Apr 12.

11.

A rare case of choroid plexus carcinoma that led to the diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer).

Zhu VW, Hinduja S, Knezevich SR, Silveira WR, DeLozier CD.

Clin Neurol Neurosurg. 2017 Jul;158:46-48. doi: 10.1016/j.clineuro.2017.04.013. Epub 2017 Apr 19.

PMID:
28460341
12.

Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?

Ou SI, Lee TK, Young L, Fernandez-Rocha MY, Pavlick D, Schrock AB, Zhu VW, Milliken J, Ali SM, Gitlitz BJ.

Lung Cancer. 2017 Apr;106:110-114. doi: 10.1016/j.lungcan.2017.02.005. Epub 2017 Feb 9.

13.

ASCEND-2: a canary in a coal mine for descending to second-line treatment for ALK-rearranged non-small cell lung cancer.

Zhu VW, Ou SI.

Transl Lung Cancer Res. 2016 Dec;5(6):660-664. doi: 10.21037/tlcr.2016.12.01. No abstract available.

14.

Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.

Ou SI, Young L, Schrock AB, Johnson A, Klempner SJ, Zhu VW, Miller VA, Ali SM.

J Thorac Oncol. 2017 Jan;12(1):137-140. doi: 10.1016/j.jtho.2016.09.119. Epub 2016 Sep 22.

15.

TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling.

Zhu VW, Upadhyay D, Schrock AB, Gowen K, Ali SM, Ou SH.

Lung Cancer. 2016 Jul;97:48-50. doi: 10.1016/j.lungcan.2016.04.013. Epub 2016 Apr 22.

PMID:
27237027

Supplemental Content

Support Center